ALINE TEOTONIO RODRIGUES, ALINE APARECIDA DA CRUZ, MÉCIA DE MARIALVA, ANTONIO LUIS EIRAS FALCÃO, PATRICIA MORIEL, PRISCILA GAVA MAZZOLA
Department of Clinical Patology - Faculty of Medical Sciences (FCM) - Unicamp, Pharmacy Service HC-Unicamp, Intensive Care Unit (ICU) HC-Unicamp
The level of technological complexity of this intensive care units (ICU), the elevated number of drugs used and the inherent difficulties in critical care are factors that highlight the need for an elaborated evaluation of drug-therapy used in intensive care medicine. The role of the clinical pharmacist, composed among other factors, by tracking and detecting potential drug interactions (PDI), can be seen as an important contribution to the quality and security of service in the ICU.
This study is based on the evaluation of a sample of medical prescriptions of ICU and aims to assess the incidence of potential drug interactions in prescriptions made in the Intensive Care Unit (ICU) of a public health hospital (Clinic Hospital - UNICAMP), to quantify and classify them according to their degree of severity, tracing with it a profile of present PDI in this setting.
From January to December 2011, prescriptions of 369 patients were evaluated, all over 18 years old, mean age of 57.03 ± 14.62, hospitalized for more than 24 hours in adult ICU. Two hundred and five different types of drugs were prescribed in the study period, average of 13.04 ± 4.26 per prescription.
Among the evaluated prescriptions, 89% presented PDI, resulting in an average of 5.00 ± 5.06 per prescription. The 405 types of observed PDI in the prescriptions were classified using Micromedex ® database, highlighting the prevalence of moderate and severe PDI present in 74% and 67% of prescriptions, respectively. In addition to the data from the pharmacotherapeutic profile of the ICU under study, statistically significant correlation among PDI and duration of hospital stay in the ICU and the number of prescription drugs was observed in the survey. The results contribute to design the risk profile relative to PDI in intensive care, showing that there is a high incidence of moderate potential drug interactions in prescriptions of ICU.
Rev.Bras. Farm. – 94 (4); 2013
Department of Clinical Patology - Faculty of Medical Sciences (FCM) - Unicamp, Pharmacy Service HC-Unicamp, Intensive Care Unit (ICU) HC-Unicamp
The level of technological complexity of this intensive care units (ICU), the elevated number of drugs used and the inherent difficulties in critical care are factors that highlight the need for an elaborated evaluation of drug-therapy used in intensive care medicine. The role of the clinical pharmacist, composed among other factors, by tracking and detecting potential drug interactions (PDI), can be seen as an important contribution to the quality and security of service in the ICU.
This study is based on the evaluation of a sample of medical prescriptions of ICU and aims to assess the incidence of potential drug interactions in prescriptions made in the Intensive Care Unit (ICU) of a public health hospital (Clinic Hospital - UNICAMP), to quantify and classify them according to their degree of severity, tracing with it a profile of present PDI in this setting.
From January to December 2011, prescriptions of 369 patients were evaluated, all over 18 years old, mean age of 57.03 ± 14.62, hospitalized for more than 24 hours in adult ICU. Two hundred and five different types of drugs were prescribed in the study period, average of 13.04 ± 4.26 per prescription.
Among the evaluated prescriptions, 89% presented PDI, resulting in an average of 5.00 ± 5.06 per prescription. The 405 types of observed PDI in the prescriptions were classified using Micromedex ® database, highlighting the prevalence of moderate and severe PDI present in 74% and 67% of prescriptions, respectively. In addition to the data from the pharmacotherapeutic profile of the ICU under study, statistically significant correlation among PDI and duration of hospital stay in the ICU and the number of prescription drugs was observed in the survey. The results contribute to design the risk profile relative to PDI in intensive care, showing that there is a high incidence of moderate potential drug interactions in prescriptions of ICU.
Rev.Bras. Farm. – 94 (4); 2013
